Curative Biotechnology

What Curative Biotechnology does

Curative Biotechnology, Inc. is a development-stage biopharmaceutical company (OTC: CUBT) that identifies, in-licenses, and develops disease-modifying therapeutic candidates concentrated on rare-disease indications across three therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. Its flagship program is a metformin-based topical ophthalmic formulation licensed exclusively worldwide from the National Eye Institute (NEI) under a Cooperative Research and Development Agreement (CRADA), targeting intermediate and late-stage Age-Related Macular Degeneration (AMD), Geographic Atrophy, and canine Progressive Retinal Atrophy. The pipeline also includes IMT504, an oligodeoxynucleotide immunotherapy in-licensed from Mid-Atlantic BioTherapeutics for symptomatic rabies and as a vaccine adjuvant, and CUBT906, a fully human CD56 monoclonal antibody drug conjugate (with a PBD cytotoxic payload) for glioblastoma, originating from the National Cancer Institute and Children's Hospital of Philadelphia.

The company's business model is asset-light and partnership-driven: management generates proof-of-principle and early clinical data in-house, then out-licenses or partners candidates with larger pharmaceutical companies for commercialization, with the intent of creating milestone payments and royalty streams rather than building its own commercial infrastructure. Manufacturing is outsourced to CDMOs such as Sterling Pharmaceutical Services. The firm is publicly traded on OTC Markets, is small (1–10 employees), is headquartered in Palm Beach Gardens, Florida, and operates a wholly owned Japanese subsidiary (Curative Biotech Japan K.K.). It is pre-revenue, recently completed a 1-for-150 reverse stock split in March 2026, and is exploring a potential uplist to OTCQB. The customer base consists of large pharmaceutical partners that will license or acquire pipeline assets; the underlying patient population comprises patients with rare diseases where no approved drug treatments currently exist.

Name

Curative Biotechnology

Legal name

Curative Biotechnology, Inc.

Website

https://curativebiotech.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Curative Biotechnology is a development-stage biopharmaceutical company (OTC: CUBT) that in-licenses and develops rare-disease therapeutics across ophthalmology, infectious disease, and neuro-oncology, using a partnership-and-licensing business model to monetize its pipeline of metformin-based eye drops, IMT504 immunotherapy, and CUBT906 antibody-drug conjugate.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Biopharmaceutical development
• Ocular therapeutics
• Rare disease drugs
• Monoclonal antibody therapy
• Immunotherapy development

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Royalty Revenue: Curative Biotech generates revenue through licensing agreements with larger pharmaceutical companies for commercialization of their drug candidates. The company creates value by developing proof-of-principle data and then licensing out or partnering with larger companies for commercialization, creating significant milestones and royalty streams.
2. Securities Offerings: The company raises capital through securities offerings to fund operations and development activities. A Form D filing indicated the company was raising $919,000, with $146,000 already sold.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Curative Biotechnology is a development-stage biopharmaceutical company that identifies, acquires, and develops disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Its pipeline spans three therapeutic areas: degenerative eye disease (proprietary metformin-based topical ophthalmic formulation for AMD and Geographic Atrophy, plus a canine K9 version), neuro-oncology (CUBT906, a fully human CD56 monoclonal antibody drug conjugate for glioblastoma), and infectious disease (IMT504, an oligodeoxynucleotide immunotherapy for symptomatic rabies and as a COVID-19 vaccine adjuvant in immunocompromised patients). The company operates a licensing and partnership business model, developing candidates through CRADAs with NIH/NEI and then licensing or partnering with larger pharmaceutical companies for commercialization.

Product overview

Curative Biotechnology is a development-stage biopharmaceutical company developing a portfolio of therapeutic drug candidates across three therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The company's core products include: (1) Metformin Reformulation/metformin-based eye drops licensed from the National Eye Institute (NEI) for treating Age-Related Macular Degeneration and geographic atrophy, also being adapted for canine (K9) retinal degeneration; (2) IMT504, an oligodeoxynucleotide immunotherapy for rabies treatment and COVID-19 vaccine adjuvant; and (3) CUBT906, a CD56 monoclonal antibody drug conjugate for glioblastoma. The company operates through strategic partnerships with NIH/NEI under CRADA agreements and licenses technology from institutions like Mid-Atlantic BioTherapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• Metformin-based Eye Drops (Ocular Metformin Reformulation)
• IMT504
• CUBT906 (CD56 Monoclonal Antibody ADC)
• Metformin-based Topical Ophthalmic Formulation for K9 (Canine)

Quantifiable outcome

• First-in-human clinical trial targeted for 2026 for metformin-based eye drops for Dry AMD
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered major and core.

• Sterling Pharmaceutical ServicesmajorTechnology or Integration · 15 April 2026Curative Biotechnology engaged Sterling Pharmaceutical Services, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation for degenerative eye diseases. The manufacturing agreement supports the Company's planned first-in-human Phase 1 clinical study in dry Age-Related Macular Degeneration and K9 clinical study targeting PDE6-associated retinal degeneration.
• National Eye Institute (NEI) / National Institutes of Health (NIH)coreStrategic or Co-development PartnerCurative Biotech collaborates with NEI under a Cooperative Research and Development Agreement (CRADA) to evaluate Curative's proprietary ocular metformin formulation in clinical studies for treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). The company has an exclusive worldwide license from NEI for intellectual property claiming the ability to use metformin to treat various types of retinal degeneration.
• Mid-Atlantic BioTherapeutics, Inc. (MABT)coreTechnology or IntegrationCurative Biotech entered into a licensing and partnering agreement with Mid-Atlantic BioTherapeutics, Inc. to acquire worldwide rights for development and commercialization of IMT504, a novel patented immunotherapy to treat symptomatic rabies.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerCUBT906 technology was originally developed at the National Cancer Institute at the NIH in collaboration with Children's Hospital of Philadelphia (CHOP). The antibody drug conjugate targets CD56 positive brain tumors.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerCollaborated with NCI and Curative Biotech on development of CUBT906 CD56 monoclonal antibody technology for targeting brain tumors.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Iveric Bio (Astellas): Acquired by Astellas for its complement C5 inhibitor Izervay for geographic atrophy. Sets the regulatory and commercial benchmark Curative's metformin ophthalmology program would need to differentiate against.
• Apellis Pharmaceuticals: Approved developer of intravitreal C3 inhibitors (Syfovre/Empaveli) for geographic atrophy and PNH. Established leader in the same GA indication Curative is pursuing via a different mechanism, illustrating both the market opportunity and the competitive benchmark.

Others

• Sterling Pharma Services: U.S.-based CDMO engaged by Curative to manufacture clinical supply of the metformin ophthalmic formulation. Listed as a peer given its role as the manufacturing infrastructure partner for the lead asset's first-in-human study.

Direct peers

• EyePoint Pharmaceuticals: Ophthalmology-focused specialty pharma developing sustained-release drug delivery formulations for retinal diseases including wet AMD. Directly comparable to Curative's topical metformin ophthalmology platform given shared focus on reformulated/repurposed ophthalmic delivery.
• Kodiak Sciences: Clinical-stage ophthalmology biotech developing novel therapeutics for retinal diseases including AMD. Comparable to Curative on therapeutic area focus and development-stage profile.
• Annexon, Inc. Clinical-stage biotech developing complement-pathway inhibitors for geographic atrophy and other ophthalmology indications. Comparable to Curative's Dry AMD/Geographic Atrophy lead program given identical target indication and rare-disease focus.
• Clene Nanomedicine: Late-stage clinical neuroscience biotech developing disease-modifying therapeutics for neurodegenerative diseases. Comparable to Curative's neuro-oncology/AMD positioning on development-stage profile and central nervous system focus.

Regional players

• Bavarian Nordic: Commercial-stage vaccine developer with an approved rabies vaccine (Rabipur) and mpox/smallpox franchises. Directly comparable to Curative's IMT504 rabies program from a competitive/indication standpoint.

Emerging players

• Krystal Biotech: Commercial-stage biotech focused on rare disease gene therapies. Comparable to Curative on rare-disease-focused development model and accelerated/regulatory pathway strategy.
• Neuralstem (acquired by NovoMed): Former company led by Curative's CEO I Richard Garr; developed small-molecule and cell therapies for CNS indications including glioblastoma. Closely tied to Curative's executive lineage and neuro-oncology interest.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/curative-biotech
• Xx.com/curativebiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curative Biotechnology